Raltegravir - 400 mg

Temporarily limited

Benefits at a glance

  • Pivotal BE mid of 2023 (400mg)
  • European manufacturing site 

Product details

Indication:

Human immunodeficiency virus (HIV) and AIDS

Strengths

400 mg

Dosage form

Tablet

API

Raltegravir

Dossier available

Q4 / 2023

Turnover

295 Mio. € (IQVIA 2021– EU)

Earliest possible launch

Upon grant of MA

Status

  • Development Kick-off
  • Formulation Development
  • Prototype
  • Pilot BE
  • Scale Up
  • Pivotal BE
  • 6 M Stability
  • Dossier
  • EU-Approval

Summary

With the Raltegravir-Dossier, which is being developed with a non-infringing polymorphic form of the API, meaning that the launch is possible prior to a 1:1 copy, we provide a widely used and effective product with a reliable supply chain.

With more than 40 million people living with HIV or AIDS worldwide, our product cannot only help a large number of people get adequate and efficient access to an effective treatment, but also can unlock a large market potential.

Your Contact

Heike Sagi

Heike Sagi

Business Development & Licensing
Senior Director

Midas Pharma GmbH
Rheinstraße 49
55218 Ingelheim
Germany
  • Disclaimer

    The exploitation, including the development, sale and offer for sale of products and related processes is performed by Midas only in those territories where permissible by applicable patent law in particular, but not limited to EC Directive 2001/83 EC, Article 10, as amended by EC Directive 2004/27 EC. This document, therefore, does not and shall not constitute an offer for sale for the product in territories where an offer for sale or sale is not permissible by law. Midas expressly disclaims any liability for the information provided in this document as well as for damages resulting from or arising out of the use of the product and related process for purposes other than research and development in compliance with applicable laws.

     

Share this page